GAIN Trial

Alzheimer’s disease is a global public health threat, affecting more than 30 million people worldwide and 5.7 million in the United States. While the number of people with the disease continues to climb, the few medications that are currently available only provide temporary symptom relief without slowing progression of the disease.  

About the GAIN Trial:

The GAIN (GingipAIN Inhibitor for Treatment of Alzheimer’s Disease) Trial is based on a growing body of scientific evidence that the bacteria P. gingivalis, most commonly associated with degenerative gum disease, can infect the brain and cause Alzheimer’s disease.

This clinical trial will evaluate whether the investigational oral drug COR388 is safe and can slow or halt the progression of Alzheimer’s disease by inactivating the toxic proteins, called gingipains, released by the bacteria and stop or slow further damage to healthy brain cells.

The GAIN Trial is looking to enroll more than 500 participants with mild to moderate Alzheimer’s disease at more than 90 clinical trial centers in the United States and Europe.  The Memory Health Center has been selected to join this research study.  

Who Is Eligible to Participate? 

Patients may qualify for this study if they: 

  • Are age 55 to 80 years old
  • Have been diagnosed with mild to moderate Alzheimer’s disease*
  • Have a friend or family member who can be a study partner and help by attending study visits, reporting on daily activities and oversee medication.

*if you are unsure of a diagnosis, the doctors at the Memory Health Center may be able to provide a no cost pre-study evaluation.  

To see if you may qualify, please call us at the number listed above in the top right corner of the page, or fill out the form to the right and we will contact you.

RELATED RESEARCH STUDIES


Currently Enrolling
shadow
Alzheimer’s disease is a progressive, degenerative disease that destroys nerve cells (neurons) in the brain.
Currently Enrolling
shadow
Early Memory Loss is a condition marked by memory loss that is annoying and frustrating to the person experiencing it, but does not significantly affect a person’s ability to function.
Currently Enrolling
shadow